Predatory Journal Trading on Former Name

Experimental & Clinical Cardiology, a once well-respected journal, now is publishing anything that comes with a payment of $1,200.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, BRYAN BRANDENBURGThe Canadian scientific journal Experimental & Clinical Cardiology used to publish well-founded studies in the field and was widely read within the cardiology community. But since being sold and moved offshore in 2013, the journal is now publishing anything submitted along with a fee of $1,200, packaging spurious studies as serious scientific papers.

A reporter from the Ottawa Citizen provided evidence that Experimental & Clinical Cardiology has gone down the tubes by submitting a manuscript under the nonsensical title, “VEGF Proliferation in Cardiac cells Contributes to Vascular Declension.” The manuscript plagiarized the main text from a published article on HIV, replacing each mention of “HIV” with the word “cardiac,” and included blank graphs. The supposedly “peer-reviewed” journal published the paper.

The journal’s previous owner, Pulsus Publishing Group, sold Experimental & Clinical Cardiology last year. Former publisher Robert Kalina told the Ottawa Citizen that he sold the journal to some “strangers from New York,” who subsequently resold it to an unknown party. The new owners claim to be in Switzerland, but according to the Ottawa Citizen, the $1,200 publishing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide